Diagnosis and management of tyrosinemia type I
The DOI matches its Crossref record.
Abstract
Hereditary tyrosinemia type I (HTI) (MIM 276700) is an autosomal recessive disorder caused by deficiency of fumarylacetoacetase (EC 3.7.1.2), which is the last enzyme in the tyrosine degradation pathway. The enzyme block causes accumulation of toxic metabolites in the liver and kidneys, which are the organs where tyrosine is mainly degraded. The disorder is characterized by severe liver disease, which either causes liver failure in infancy or may take a more protracted course, with death often occurring during childhood or adolescence because of hepatoma development. Treatment with a diet restricted in phenylalanine nd tyrosine does not prevent progression of the liver disease and development of hepatocellular carcinoma. Liver transplantation was previously the only option for these patients. Important achievements from metabolic and molecular biology studies of the disease include a new treatment for patients with HTI using an enzyme inhibitor, detection of self-induced correction of the genetic defect in regenerative liver nodules in HTI patients, identification and development of useful animal models for HTI, and studies of the molecular genetics of HTI. These advances will have great implications for our understanding of pathogenetic mechanisms, which is the basis for improved diagnostic methods and improved treatment of patients with HTI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Tyrosinaemia type I and NTBC (2‐(2‐nitro‐4‐trifluoromethylbenzoyl)‐1,3‐cyclohexanedione)
Holme, E., & Lindstedt, S. (1998) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1005410820201 · Cited by 264
Self-citationNTBC treatment in tyrosinaemia type I: Long‐term outcome in French patients
Masurel‐Paulet, A., Poggi‐Bach, J., Rolland, M. ‐., Bernard, O., Guffon, N., Dobbelaere, D., Sarles, J., de Baulny, H. O., & Touati, G. (2008) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-008-0793-1 · Cited by 212
“This metabolic block allows the suppression of MAA, FAA and SA toxic accumulation but does not prevent the accumulation of tyrosine (Holme and Lindstedt 1995; Lindstedt et al 1992; Lock et al 1998).”
BackgroundHall, M. G., Wilks, M. F., Provan, W. M., Eksborg, S., & Lumholtz, B. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01421.x · Cited by 110
Crone, J., Möslinger, D., Bodamer, O., Schima, W., Huber, W., Holme, E., & Ipsiroglu, S. S. (2003) · Acta Paediatrica · doi:10.1111/j.1651-2227.2003.tb02518.x · Cited by 34
Self-citationSingle dose NTBC‐treatment of hereditary tyrosinemia type I
Schlune, A., Thimm, E., Herebian, D., & Spiekerkoetter, U. (2012) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-012-9450-9 · Cited by 33
Metadata
- Authors
- Holme, E., & Lindstedt, S.
- Venue
- The Journal of Pediatrics
- Published
- 1995
- Volume
- 7
- Issue
- 6
- Pages
- 726-732
- ISSN
- 0022-3476 (ISSN-L)
- OpenAlex
- W2401569593
- Cited by
- 65
- References
- 0
- FWCI
- 0.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diagnosis and management of tyrosinemia type I. https://app.cochat.ai/papers/10.1097/00008480-199512000-00017
- The paper
- Holme, E., & Lindstedt, S. (1995). Diagnosis and management of tyrosinemia type I. The Journal of Pediatrics. https://doi.org/10.1097/00008480-199512000-00017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.